Amgen announced that a Delaware jury delivered a verdict in Amgen’s favor in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9).
Amgen brought the patent infringement action in Federal Court in Delaware against Sanofi and Regeneron Pharmaceuticals, Inc. (collectively “Defendants”). Before trial, Sanofi and Regeneron acknowledged infringement of seven patent claims in U.S. Patent Numbers 8,829,165, and 8,859,741. The trial proceeded on Defendants’ challenges to the validity of those seven claims. The jury found that Defendants had failed to prove the patents invalid for lack of written description and enablement. Prior to the case going to the jury, the Court dismissed Defendants’ case on obviousness.
Robert A. Bradway , chairman and chief executive officer at Amgen said, We are thankful that the jury weighed the evidence carefully and recognized the validity of Amgen’s patents on Repatha, our innovative biologic molecule that reduces LDL cholesterol.